Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first-line recurrent/metastatic HNSCC

Bookmark and Share
Published: 14 Sep 2022
Views: 54
Rating:
Save
Dr Marcin Dzienis - Gold Coast University Hospital, Southport, Australia

Dr Marcin Dzienis speaks to ecancer about phase IV of the KEYNOTE-B10 study which explored pembrolizumab with carboplatin and paclitaxel as first-line therapy in recurrent or metastatic head and neck squamous cell carcinoma.  

The primary endpoint was overall response rate per RECIST v1.1 by blinded independent central review (BICR). The secondary endpoints were duration or response and progression free survival by BICR, overall survival, safety and tolerability. 

The results of the study concluded that pembrolizumab/carboplatin/paclitaxel combo showed antitumour activity with a manageable safety profile, suggesting this 5-FU-free regimen may be comparable to historica lfirst-line standard of care and may expand treatment options for first-line recurrent or metastatic head and neck squamous cell carcinoma.